Stock INDSWFTLAB IND-SWIFT LABORATORIES LIMITED
Add to a list

Ind-Swift Laboratories Limited Share Price Bombay S.E.

Stocks

INDSWFTLAB

INE915B01019

Pharmaceuticals

Delayed Bombay S.E.
Other stock markets
 01:10:20 09/07/2026 pm IST 		5-day change 1st Jan Change
234.45 INR +4.55% Intraday chart for Ind-Swift Laboratories Limited +13.72% +165.90%
22/06 Ind-Swift Laboratories Limited Announces Resignation of Prabhat Khurana as Independent Director and Committees, Effective June 22, 2026 CI
28/05 Ind-Swift Laboratories Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2026 CI

Valuation: Ind-Swift Laboratories Limited

Market Cap 1.14TCr 12Cr 10Cr 9.64Cr 8.91Cr 17Cr 17Cr 115.86Cr 45Cr 557.7Cr 45Cr 44Cr 1.94TCr P/E 2024
1.41x
P/E 2025 2.38x
Enterprise Value 713.1Cr 7.45Cr 6.53Cr 6.03Cr 5.57Cr 11Cr 11Cr 72Cr 28Cr 348.97Cr 28Cr 27Cr 1.21TCr EV / Sales 2024
0.14x
EV / Sales 2025 0.12x
Free-Float
40.72%
Yield 2024 *
-
Yield 2025 -
* Estimated data More valuation ratios

Chart: Ind-Swift Laboratories Limited

Dynamic Chart

Latest news : Ind-Swift Laboratories Limited

22/06 Ind-Swift Laboratories Limited Announces Resignation of Prabhat Khurana as Independent Director and Committees, Effective June 22, 2026 CI
28/05 Ind-Swift Laboratories Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2026 CI
07/04 Ind Swift Laboratories says tribunal rejected all claims of PI Industries, counterclaims of co, others RE
16/02 Ind Swift Laboratories Ltd to invest 400 million rupees in Samba facility upgrade RE
16/02 Ind-Swift Laboratories Limited to Upgrade Samba Facility with an Investment of 400 Million CI
31/01 Ind-Swift Laboratories Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2025 CI
16/12 Ind-Swift Laboratories' Derabassi Facility Gets GMP Certification from Hungary MT
14/11 Ind-Swift Laboratories Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2025 CI
17/25/17 Emerald Finance Secures Contract to Offer Early-Wage-Access Program; Shares Up 4% MT
13/25/13 Ind-Swift Laboratories Limited Reports Earnings Results for the First Quarter Ended June 30, 2025 CI
11/25/11 Ind-Swift Laboratories Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2025 CI
08/25/08 Ind-Swift Laboratories Limited Completed the acquisition of Ind-Swift Limited. CI
17/25/17 Ind Swift says NCLT approves amalgamation of Ind-Swift Limited with Ind-Swift Laboratories RE
More news

Press Releases: Ind-Swift Laboratories Limited

07/23/07 IndiaRF to acquire API and CRAMS business of Ind-Swift Laboratories Limited for INR 1,650 Crores AQ
More press releases

Quotes and Performance

1 day+4.57%
1 week+13.72%
Current month+15.35%
1 month+45.11%
3 months+63.53%
6 months+158.54%
Current year+165.90%
More quotes

Course Extremes

1 week 206.55
Extreme 206.55
 238
1 month 158
Extreme 158
 238
Current year 88.5
Extreme 88.5
 238
1 year 87
Extreme 87
 238
3 years 67.15
Extreme 67.15
 238
5 years 51.1
Extreme 51.1
 238
10 years 15.25
Extreme 15.25
 238
More quotes

Managers and Directors: Ind-Swift Laboratories Limited

Manager TitleAgeSince
Navrattan R. Munjal CEO
 Chief Executive Officer 74 04/01/1995
Himanshu Jain CEO
 Chief Executive Officer 43 15/06/2011
Gagan Aggarwal DFI
 Director of Finance/CFO - 29/09/2018
Director TitleAgeSince
Himanshu Jain BRD
 Director/Board Member 43 -
Navrattan R. Munjal CHM
 Chairman 74 -
Rishav Mehta BRD
 Director/Board Member 35 23/03/2010
More insiders

Generic Pharmaceuticals

Add to a list

0 selected

To use this feature you must be a member
Log inSign up
 Change 5-day change 1-year change 3-year change Capi.($)
IND-SWIFT LABORATORIES LIMITED Stock Ind-Swift Laboratories Limited
+4.55%+13.72% - - 20Cr
SUN PHARMACEUTICAL INDUSTRIES LTD. Stock Sun Pharmaceutical Industries Ltd.
+2.53%+3.52%+16.02%+85.35% 4.73TCr
OTSUKA HOLDINGS CO., LTD. Stock Otsuka Holdings Co., Ltd.
-0.81%-4.53%+65.57%+113.67% 3.6TCr
CIPLA LIMITED Stock Cipla Limited
+1.29%-0.38%-2.76%+42.67% 1.21TCr
ZYDUS LIFESCIENCES LIMITED Stock Zydus Lifesciences Limited
+0.95%+5.37%+18.44%+99.26% 1.2TCr
KRKA, D. D. Stock Krka, d. d.
+0.86%+1.95%+34.36%+123.93% 905.07Cr
GEDEON RICHTER Stock Gedeon Richter
+0.08%-0.50%+17.56%+44.31% 691.7Cr
ONO PHARMACEUTICAL CO., LTD. Stock Ono Pharmaceutical Co., Ltd.
-1.61%+1.96%+54.90%-2.70% 719.04Cr
GLENMARK PHARMACEUTICALS LIMITED Stock Glenmark Pharmaceuticals Limited
+2.40%+3.72%+25.23%+243.13% 655.37Cr
SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. Stock Shenzhen Salubris Pharmaceuticals Co., Ltd.
-7.00%+5.26%-20.00%+10.09% 589.9Cr
Average +0.36%+1.69%+23.26%+84.41% 1.59TCr
Weighted average by Cap. +0.66%+2.11%+29.25%+90.20%
See all sector performances

Financials

2024 2025
Net sales 1.3TCr 14Cr 12Cr 11Cr 10Cr 19Cr 20Cr 131.89Cr 51Cr 634.83Cr 51Cr 50Cr 2.2TCr 561.71Cr 5.87Cr 5.15Cr 4.75Cr 4.39Cr 8.32Cr 8.49Cr 57Cr 22Cr 274.88Cr 22Cr 22Cr 954.22Cr
Net income 420.96Cr 4.4Cr 3.86Cr 3.56Cr 3.29Cr 6.24Cr 6.36Cr 43Cr 17Cr 206Cr 17Cr 16Cr 715.12Cr 250.48Cr 2.62Cr 2.29Cr 2.12Cr 1.96Cr 3.71Cr 3.78Cr 25Cr 9.89Cr 122.57Cr 9.82Cr 9.61Cr 425.5Cr
Net Debt -415.31Cr -4.34Cr -3.8Cr -3.51Cr -3.25Cr -6.15Cr -6.27Cr -42Cr -16Cr -203.23Cr -16Cr -16Cr -705.51Cr -426.55Cr -4.45Cr -3.91Cr -3.61Cr -3.33Cr -6.32Cr -6.44Cr -43Cr -17Cr -208.74Cr -17Cr -16Cr -724.61Cr
* Estimated data More financial data

Company Profile

Logo Ind-Swift Laboratories Limited
Ind-Swift Laboratories Limited is an India-based company, which is engaged in the business of manufacturing active pharmaceutical ingredients (APIs), intermediates and formulations. The Company operates in the Pharmaceutical Business segment. It also focuses on manufacturing formulations. The Company’s products include APIs and Impurities. Its APIs therapeutic category includes Macrolide Antibiotic, Cardiovascular, Antihistaminic, Antidiabetic, Antipsyhotic, Bone Resorption Inhibitor, and Aromatase Inhibitor. Its products include Clarithromycin, Clarithromycin Coated Granules, Clarithromycin Citrate, Atorvastatin Calcium Crystalline, Atorvastatin Calcium Amorphous, Clopidogrel HCl, Ezetimibe, Ivabradine Oxalate, Ranolazine, Aripiprazole, Risedronate Sodium, Ropinirole HCl, Cinacalcet HCl, Letrozole, and Anastrozole. Its products under development include Sitagliptin Phosphate, Mirabegron, Bempedoic Acid, Lasmiditan, and Eltrombopag Olamine.
Employees
1,246
Sector
Pharmaceuticals
More about the company

Quotes

Date Price Change Volume
09/26/09 ₹234.45 +4.55% 55,839
08/26/08 ₹224.25 +4.13% 2,59,527
07/26/07 ₹215.35 -2.86% 38,345
06/26/06 ₹221.70 +3.57% 1,03,205
03/26/03 ₹214.05 +3.81% 83,281

Delayed Quote Bombay S.E.

More quotes

Income Statement and Estimates

More financial data
  1. Stock Market
  2. Stocks
  3. INDSWFTLAB Stock
  4. INDSWFTLAB Stock

Select your edition

All financial news and data tailored to specific country editions

NORTH AMERICA

MarketScreener
United-States
MarketScreener Canada
Canada

MIDDLE EAST

MarketScreener Saudi Arabia
Saudi Arabia
MarketScreener UAE Emirates
United Arab Emirates

EUROPE

Zonebourse
France
MarketScreener Deutschland
Deutschland
Zonebourse Suisse
Suisse
MarketScreener Schweiz
Schweiz
MarketScreener Italia
Italia
MarketScreener Österreich
Österreich
MarketScreener België
België
MarketScreener Nederland
Nederland
MarketScreener España
España
MarketScreener Sverige
Sverige
MarketScreener UK
United Kingdom

APAC

MarketScreener Australia
Australia
MarketScreener India
India
MarketScreener Hong Kong
Hong Kong